Related Experiment Video

Updated: May 21, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

β-catenin inhibition synergizes with imatinib to delay CML recurrence

    Cancer Discovery
    |June 12, 2012
    PubMed

    Insights

    Targeting beta-catenin in chronic myeloid leukemia (CML) stem cells halts their self-renewal. This discovery offers a new therapeutic strategy for CML treatment.

    Area of Science:

    • Hematology
    • Molecular Biology
    • Cancer Research

    Background:

    • Chronic myeloid leukemia (CML) is driven by leukemic stem cells (LSCs) that resist conventional therapies.
    • The Wnt/beta-catenin signaling pathway is implicated in stem cell self-renewal and cancer progression.

    Purpose of the Study:

    • To investigate the role of beta-catenin in CML stem cell self-renewal.
    • To evaluate the therapeutic potential of targeting beta-catenin in CML.

    Main Methods:

    • Utilized genetic and pharmacologic approaches to inhibit beta-catenin in CML stem cells.
    • Assessed the impact of beta-catenin inhibition on stem cell self-renewal capacity.

    Main Results:

    • Both genetic and pharmacologic inhibition of beta-catenin effectively blocked CML stem cell self-renewal.
    • This suggests beta-catenin is essential for maintaining the CML stem cell pool.

    Conclusions:

    • Beta-catenin is a critical regulator of self-renewal in CML stem cells.
    • Targeting beta-catenin presents a promising therapeutic strategy for eradicating CML stem cells and achieving durable remission.

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Inhibition of CDK Activity02:34

    Inhibition of CDK Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...